Executive interview – InMed: A leader in the development of cannabinol (CBN) therapeutics

Published on 20 January 2020

InMed is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.

InMed is a biopharmaceutical company focused on manufacturing and developing cannabinoids. Its main pipeline product is INM-755 for epidermolysis bullosa, a serious, debilitating orphan indication.

Share this with friends and colleagues